CA
AZN icon

Continental Advisors’s AstraZeneca AZN Stock Holding History

Continental Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-37,900
Closed -$2.25M – 130
2013
Q4 		$2.25M Sell
37,900
-25,000
-40% -$1.36M 0.49% 64
2013
Q3 		$3.27M Buy
+62,900
New +$3.16M 0.81% 33

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Continental Advisors's AZN Position: Q3 2020 in Review

Continental Advisors sold out of AstraZeneca (AZN) in Q3 2020, closing a stake of 2,165 shares — an estimated $229K sold.

Continental Advisors first reported a position in AZN in Q2 2013 and held it in 29 quarters. The position peaked at $3.5M in Q3 2017. 722 funds tracked by Wall St. Rank hold AZN as of Q3 2020.

  • Continental Advisors reported no remaining AstraZeneca position as of Q3 2020 after selling out during the quarter.
  • Continental Advisors sold 2,165 AstraZeneca shares in Q3 2020, an estimated $229K.
  • Continental Advisors first reported a position in AstraZeneca in Q2 2013 and held it in 29 quarters.
  • Continental Advisors's AstraZeneca position peaked at $3.5M in Q3 2017.
  • 722 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2020.

Based on Continental Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.